Orion Pharma (DHA:ORIONPHARM) Piotroski F-Score: 5 (As of Jul. 13, 2026) — 17% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT30.10
GF Value BDT20.18
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Piotroski F-Score?

Orion Pharma DHA:ORIONPHARM +0.33% 72 Piotroski F-Score is 5 as of Jul. 13, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.18 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 417 Utilities - Independent Power Producers companies, Orion Pharma ranks better than 61.39% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Orion Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Orion Pharma's Piotroski F-Score or its related term are showing as below:

DHA:ORIONPHARM' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 7
Current: 5

During the past 12 years, the highest Piotroski F-Score of Orion Pharma was 7. The lowest was 4. And the median was 6.

Orion Pharma  (DHA:ORIONPHARM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Orion Pharma Piotroski F-Score Related Terms


Orion Pharma Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Piotroski F-Score Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 6.00 6.00 4.00

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 5.00 5.00 5.00

DHA:ORIONPHARM vs CEG, VST, NRG: Piotroski F-Score Comparison

For the Utilities - Independent Power Producers subindustry, Orion Pharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Pharma Piotroski F-Score vs Utilities - Independent Power Producers Industry

For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Orion Pharma's Piotroski F-Score falls into.


DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -373.909 + -69.717 + -131.567 + -151.677 = BDT-727 Mil.
Cash Flow from Operations was -129.345 + 150.986 + 459.397 + 340.76 = BDT822 Mil.
Revenue was 729.83 + 794.522 + 748.154 + 1486.759 = BDT3,759 Mil.
Gross Profit was 139.143 + 334.288 + 325.271 + 625.747 = BDT1,424 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(54652.296 + 55796.148 + 57156.821 + 56903.504 + 57143.737) / 5 = BDT56330.5012 Mil.
Total Assets at the begining of this year (Mar25) was BDT54,652 Mil.
Long-Term Debt & Capital Lease Obligation was BDT26,615 Mil.
Total Current Assets was BDT17,495 Mil.
Total Current Liabilities was BDT8,500 Mil.
Net Income was -68.017 + 55.396 + -102.591 + 5.824 = BDT-109 Mil.

Revenue was 2840.369 + 1646.542 + 860.395 + 845.074 = BDT6,192 Mil.
Gross Profit was 560.902 + 448.71 + 380.96 + 415.629 = BDT1,806 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(52319.604 + 54432.779 + 53783.08 + 54289.405 + 54652.296) / 5 = BDT53895.4328 Mil.
Total Assets at the begining of last year (Mar24) was BDT52,320 Mil.
Long-Term Debt & Capital Lease Obligation was BDT23,169 Mil.
Total Current Assets was BDT17,098 Mil.
Total Current Liabilities was BDT8,600 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Orion Pharma's current Net Income (TTM) was -727. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Orion Pharma's current Cash Flow from Operations (TTM) was 822. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-726.87/54652.296
=-0.0132999

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-109.388/52319.604
=-0.00209077

Orion Pharma's return on assets of this year was -0.0132999. Orion Pharma's return on assets of last year was -0.00209077. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Orion Pharma's current Net Income (TTM) was -727. Orion Pharma's current Cash Flow from Operations (TTM) was 822. ==> 822 > -727 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=26615.494/56330.5012
=0.47248814

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=23169.261/53895.4328
=0.42989285

Orion Pharma's gearing of this year was 0.47248814. Orion Pharma's gearing of last year was 0.42989285. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=17494.994/8499.865
=2.05826728

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=17098.304/8600.429
=1.98807571

Orion Pharma's current ratio of this year was 2.05826728. Orion Pharma's current ratio of last year was 1.98807571. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Orion Pharma's number of shares in issue this year was 234. Orion Pharma's number of shares in issue last year was 234. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1424.449/3759.265
=0.37891689

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1806.201/6192.38
=0.29168123

Orion Pharma's gross margin of this year was 0.37891689. Orion Pharma's gross margin of last year was 0.29168123. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=3759.265/54652.296
=0.06878512

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=6192.38/52319.604
=0.11835678

Orion Pharma's asset turnover of this year was 0.06878512. Orion Pharma's asset turnover of last year was 0.11835678. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Orion Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Orion Pharma (DHA:ORIONPHARM) has a Piotroski F-Score of 5 as of Jul. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Orion Pharma and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Orion Pharma's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Orion Pharma ranks #161 out of 417 companies in the Utilities - Independent Power Producers industry, placing it in the top 38.6%.
Is Orion Pharma's Piotroski F-Score too high?
Orion Pharma's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Utilities - Independent Power Producers industry median Piotroski F-Score is 5.00. Orion Pharma's value of 5 is 0% at this industry median. Based on the distribution chart, Orion Pharma ranks #161 out of 417 companies in the Utilities - Independent Power Producers industry, which is above the industry midpoint. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Piotroski F-Score compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #161 out of 417 companies for Piotroski F-Score. This puts Orion Pharma in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Orion Pharma's value of 5 is 0% at this benchmark. Historically, Orion Pharma's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Orion Pharma has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for an Utilities - Independent Power Producers company?
The median Piotroski F-Score among Utilities - Independent Power Producers companies is 5.00, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.18, compared to a current price of BDT30.10 — trading 49.2% above its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Utilities - Independent Power Producers industry median of 5.00. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Piotroski F-Score is 5 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.10 is trading 49.2% above its estimated GF Value™ of BDT20.18. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: BDT20.18 vs. price of BDT30.10 (49.2% above fair value)
  • GF Score™: 72/100 with 8 warning signs
  • Industry Position: 0% at the Utilities - Independent Power Producers median (#161 of 417)

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.10
Price
BDT20.18
GF Value